INTRODUCTION: The purpose of this study was to determine the role of the injected dose of tracer in the non-detection of pelvic sentinel lymph nodes (SLN) in patients with prostate carcinoma. METHODS: Data were evaluated from 100 patients (age range 43-77, mean 63 years). The first 72 patients (group 1) received 2 x 0.3 ml of 30 MBq-nanocolloid-99 mTc and the remaining 28 patients (group 2) received 2 x 0.3 ml of 100 MBq. Surgery consisted of the detection and dissection of lymph nodes identified as sentinel nodes, followed by an extended lymphadenectomy. RESULTS: SLNs were located in the interiliac group in 54.2% of patients, in the obturator fossa in 30.7%, in the external iliac group in 10.9% and in the common iliac group in 4.2% of cases. Lymph node involvement was observed in 12% of patients. But there was a 30.6% (22/72) failure rate of the SLN procedure in group 1 and 7.1% (2/28) in group 2. An increased risk of unsuccessful SLN procedure was statistically associated with the low dose of MBq-nanocolloids (p < 0.017). Statistical correlation is also found after the exclusion of the first 30 patients from the study (learning phase of the team) (p < 0.034). None of the other parameters showed a statistical association (age, p < 0.9; Gleason score, p < 0.3; grade pT, p < 0.7). A higher grade or a greater extension of cancer inside the prostate are not responsible for the failure of the SLN procedure. CONCLUSION: It seems necessary to inject at least 200 MBq inside the prostate to avoid a failed SLN procedure.
INTRODUCTION: The purpose of this study was to determine the role of the injected dose of tracer in the non-detection of pelvic sentinel lymph nodes (SLN) in patients with prostate carcinoma. METHODS: Data were evaluated from 100 patients (age range 43-77, mean 63 years). The first 72 patients (group 1) received 2 x 0.3 ml of 30 MBq-nanocolloid-99 mTc and the remaining 28 patients (group 2) received 2 x 0.3 ml of 100 MBq. Surgery consisted of the detection and dissection of lymph nodes identified as sentinel nodes, followed by an extended lymphadenectomy. RESULTS: SLNs were located in the interiliac group in 54.2% of patients, in the obturator fossa in 30.7%, in the external iliac group in 10.9% and in the common iliac group in 4.2% of cases. Lymph node involvement was observed in 12% of patients. But there was a 30.6% (22/72) failure rate of the SLN procedure in group 1 and 7.1% (2/28) in group 2. An increased risk of unsuccessful SLN procedure was statistically associated with the low dose of MBq-nanocolloids (p < 0.017). Statistical correlation is also found after the exclusion of the first 30 patients from the study (learning phase of the team) (p < 0.034). None of the other parameters showed a statistical association (age, p < 0.9; Gleason score, p < 0.3; grade pT, p < 0.7). A higher grade or a greater extension of cancer inside the prostate are not responsible for the failure of the SLN procedure. CONCLUSION: It seems necessary to inject at least 200 MBq inside the prostate to avoid a failed SLN procedure.
Authors: Naomi Alazraki; Edwin C Glass; Frank Castronovo; Renato A Valdés Olmos; Donald Podoloff Journal: J Nucl Med Date: 2002-10 Impact factor: 10.057
Authors: Stefan Corvin; David Schilling; Kai Eichhorn; Ilse Hundt; Joerg Hennenlotter; Aristotelis G Anastasiadis; Markus Kuczyk; Roland Bares; Arnulf Stenzl Journal: Eur Urol Date: 2005-12-09 Impact factor: 20.096
Authors: Axel Häcker; Stefan Jeschke; Karl Leeb; Kurt Prammer; Josef Ziegerhofer; Wolfgang Sega; Werner Langsteger; Guenter Janetschek Journal: J Urol Date: 2006-11 Impact factor: 7.450
Authors: Friedhelm Wawroschek; Harry Vogt; Hermann Wengenmair; Dorothea Weckermann; Michael Hamm; Mathias Keil; Gerhard Graf; Peter Heidenreich; Rolf Harzmann Journal: Urol Int Date: 2003 Impact factor: 2.089
Authors: Lenka Vermeeren; Sara H Muller; Willem Meinhardt; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-20 Impact factor: 9.236
Authors: Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin Journal: World J Surg Oncol Date: 2009-01-27 Impact factor: 2.754
Authors: Yvonne H W Derks; Dennis W P M Löwik; J P Michiel Sedelaar; Martin Gotthardt; Otto C Boerman; Mark Rijpkema; Susanne Lütje; Sandra Heskamp Journal: Theranostics Date: 2019-09-20 Impact factor: 11.556